Nucynta ER 200 mg/1 (Tapentadol Hydrochloride TABLET, FILM COATED, EXTENDED RELEASE) 200 mg/1

Nucynta ER 200 mg is an extended-release tablet containing tapentadol hydrochloride, used for managing moderate to severe pain. This prescription medication is designed for around-the-clock pain relief.

Strength

200 mg/1

Pack Size

60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24510-232-60)

Manufacturer / TM Owner

Collegium Pharmaceutical, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Nucynta ER 200 mg is primarily used for the management of moderate to severe chronic pain that requires continuous, long-term treatment. It is often prescribed for conditions that necessitate extended pain relief, such as neuropathic pain or musculoskeletal pain. The extended-release formulation is intended to provide sustained pain relief over an extended period, reducing the need for frequent dosing.

Side Effects

Common effects of Nucynta ER 200 mg may include dizziness, nausea, constipation, and headache. Some users may also experience fatigue or dry mouth. These effects can vary in intensity and duration depending on individual factors.

Precautions & Warnings

Nucynta ER 200 mg should be handled with care and stored securely to prevent misuse. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication should not be crushed, chewed, or broken, as it is designed for extended release.

Avoid Interactions

Nucynta ER 200 mg may interact with other medications, including central nervous system depressants, alcohol, and certain antidepressants. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Nucynta ER 200 mg is used for managing moderate to severe chronic pain that requires continuous, long-term treatment.

Nucynta ER 200 mg should be taken orally, whole, with or without food, as directed by a healthcare professional.

Common side effects may include dizziness, nausea, constipation, and headache.

No, Nucynta ER 200 mg should not be crushed, chewed, or broken as it is designed for extended release.

If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double the dose to catch up.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.